아시아태평양의 핵산 치료제 CDMO 시장(2023-2033년)

“The Asia-Pacific Nucleic Acid Therapeutics CDMO Market Expected to Reach $4.04 Billion by 2033.”

Introduction to Asia-Pacific (APAC) Nucleic Acid Therapeutics CDMO Market

The APAC Nucleic Acid Therapeutics CDMO Market is expected to grow at a CAGR of 13.92% from $0.97 billion in 2022 to $4.04 billion by 2033 in the forecasted period of 2023-2033. The increasing incidence of hereditary and chronic illnesses, improvements in nucleic acid production, a rise in regulatory approvals, and an expanding CDMO manufacturing infrastructure are all expected to contribute to the significant growth of the APAC nucleic acid therapies CDMO market in the years to come. With the increasing demand for nucleic acid therapeutics, CDMOs will be essential in enabling patients all around the world to access these cutting-edge treatments.

Market Introduction

With the rising incidence of genetic and chronic illnesses, growing regulatory approvals, growing CDMO manufacturing infrastructure, and encouraging government initiatives, the APAC nucleic acid therapeutics CDMO market is expected to grow significantly in the next years. With the increasing demand for nucleic acid therapeutics, CDMOs will be essential in enabling patients all around the world to access these cutting-edge treatments.

Market Segmentation:

Segmentation 1: by Chemical Synthesis Method

• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

Segmentation 2: by Country

• China
• Japan
• India
• Australia
• Rest-of-Asia-Pacific

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific nucleic acid therapeutics CDMO market:

• Increasing Presence of Established Players in the Region
• Funding Support and Investments from the Government
• Low Cost of Manufacturing

The market is expected to face some limitations as well due to the following challenges:

• Lack of Expertise in Developing Nucleic Acid Therapeutics

How can this report add value to an organization?

Product/Innovation Strategy: The nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as product, chemical synthesis method, disease type, technology, and end users. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: Key players in the Asia-Pacific nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

The Asia-Pacific nucleic acid therapeutics CDMO market has witnessed several investments for the expansion of CDMO manufacturing units by the market players. The expansion is aimed at increasing the manufacturing capacity. To meet the growing demand for their services, CDMOs are expanding their manufacturing units and investing in new technologies. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Table of Contents

1 Market

• 1.1 Global Market Outlook
  • 1.1.1 Market Overview
  • 1.1.2 Product Definition
  • 1.1.3 Inclusion and Exclusion Criteria
  • 1.1.4 Key Findings
• 1.2 Industry Outlook
  • 1.2.1 Key Trends
    • 1.2.1.1 Significant Number of Collaborations among Market Players
    • 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
    • 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
  • 1.2.2 Opportunity Assessment
  • 1.2.3 Preferred Techniques By CDMO
    • 1.2.3.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
    • 1.2.3.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
    • 1.2.3.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
  • 1.2.4 Factors Considered While Outsourcing To CDMO.
• 1.3 Impact of COVID-19 on the Global Nucleic Acid Therapeutics CDMO
  • 1.3.1 Pre-COVID-19 Phase
  • 1.3.2 During COVID-19
  • 1.3.3 Post-COVID-19 Phase
    • 1.3.3.1 Impact on Demand and Supply
• 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
• 1.5 Significant Usage of Nucleic Acid in Therapeutics
• 1.6 Types of Nucleic Acid Synthesized for Therapeutics
  • 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
  • 1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
  • 1.6.3 MicroRNAs (miRNAs)
  • 1.6.4 RNA Aptamers and RNA Decoys
  • 1.6.5 Ribozymes
  • 1.6.6 Circular RNAs
• 1.7 Business Dynamics
  • 1.7.1 Impact Analysis
  • 1.7.2 Business Drivers
    • 1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
    • 1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
    • 1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
  • 1.7.3 Business Restraints
    • 1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
    • 1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
  • 1.7.4 Business Opportunities
    • 1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
    • 1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2 Nucleic Acid Therapeutics CDMO Market (by Region)

• 2.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
    • 2.1.3.2 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country)
      • 2.1.3.2.1 Japan
        • 2.1.3.2.1.1 Japan Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.2 China
        • 2.1.3.2.2.1 China Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.3 India
        • 2.1.3.2.3.1 India Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.4 Australia
        • 2.1.3.2.4.1 Australia Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.5 Rest-of-Asia-Pacific
        • 2.1.3.2.5.1 Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Key Strategies and Developments
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 New Offerings
    • 3.1.1.3 Mergers and Acquisitions
    • 3.1.1.4 Partnerships and Collaborations
    • 3.1.1.5 Business Expansions
    • 3.1.1.6 Regulatory and Legal Activities
  • 3.1.2 Market Share Analysis
  • 3.1.3 Visual Graphics of Key Companies
• 3.2 Company Profile
  • 3.2.1 Asymchem Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Role of Asymchem Inc. in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.1.3 Financials
    • 3.2.1.4 Recent Developments
    • 3.2.1.5 Analyst Perspective
  • 3.2.2 BioCina
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Role of BioCina in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.2.3 Recent Developments
    • 3.2.2.4 Analyst Perspective
  • 3.2.3 CMIC HOLDINGS Co., Ltd.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Role of CMIC HOLDINGS Co., Ltd. In the Nucleic Acid Therapeutics CDMO Market
    • 3.2.3.3 Financials
    • 3.2.3.4 Analyst Perspective
  • 3.2.4 Kaneka Corporation
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Role of Kaneka Corporation in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.4.3 Financials
    • 3.2.4.4 Recent Developments
    • 3.2.4.5 Analyst Perspective
  • 3.2.5 Nippon Shkubai Co., Ltd
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Role of Nippon Shokubai Co., Ltd in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.5.3 Financials
    • 3.2.5.4 Analyst Perspective
  • 3.2.6 Nitto Group
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Role of Nitto Group in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.6.3 Financials
    • 3.2.6.4 Recent Developments
    • 3.2.6.5 Analyst Perspective
  • 3.2.7 ST Pharm
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Role of ST Pharm in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.7.3 Financials
    • 3.2.7.4 Recent Developments
    • 3.2.7.5 Analyst Perspective